Clinical Trial Phases Explained: Phase 1 to Phase 4
Published March 28, 2026 · ClinicalTrials.gov data
Every new medical treatment must pass through a rigorous multi-phase testing process before reaching patients. Each phase answers different questions — from "Is this safe?" to "Does this work better than existing treatments?" Here is what happens in each phase, with real trial counts from our database.
Important: This is educational information, not medical advice. Talk to your doctor about whether a clinical trial is right for you.
The Four Phases
| Phase | Purpose | Size | Duration | Recruiting Now |
|---|---|---|---|---|
| Phase 1 | Safety, dosing | 20-80 | 6-12 months | ~1,500 |
| Phase 2 | Efficacy, side effects | 100-300 | 1-2 years | ~2,800 |
| Phase 3 | Definitive efficacy | 1,000-3,000 | 2-4 years | ~2,200 |
| Phase 4 | Post-approval monitoring | Varies | Ongoing | ~800 |
Phase 1: Is It Safe?
Phase 1 is the first time a treatment is tested in humans. The primary goal is to determine safe dosage levels and identify side effects. Participants are usually healthy volunteers (for non-cancer drugs) or patients who have exhausted standard treatments (for cancer drugs). These trials are small — typically 20-80 participants.
Phase 2: Does It Work?
Phase 2 trials test whether the treatment actually works for the target condition. They also continue monitoring safety with a larger group (100-300 participants). This is where many drugs fail — roughly 50-60% of drugs that pass Phase 1 do not demonstrate sufficient efficacy to advance.
Phase 3: The Definitive Test
Phase 3 trials are the gold standard. They compare the new treatment against the current best treatment (or placebo, if no standard treatment exists) in large groups of 1,000-3,000+ patients. These are typically randomized, double-blind trials — neither the patient nor the doctor knows who receives the experimental treatment. FDA approval decisions are primarily based on Phase 3 results.
Phase 4: Real-World Monitoring
Phase 4 trials study FDA-approved treatments in broader real-world populations. They monitor long-term safety, identify rare side effects, and explore new uses. From a patient perspective, Phase 4 trials carry the least uncertainty because the treatment has already been approved.
For guidance on finding trials, see how to find a clinical trial. For cancer-specific trials, see cancer trials recruiting now.
Frequently Asked Questions
What is the difference between Phase 1, 2, 3, and 4 trials?
Phase 1 tests safety and dosing in a small group (20-80). Phase 2 tests effectiveness in a larger group (100-300). Phase 3 is the definitive test comparing the new treatment to existing treatments in a large group (1,000-3,000). Phase 4 monitors already-approved treatments in real-world use.
Which phase of clinical trial is most risky?
Phase 1 trials carry the most uncertainty because the treatment has never been tested in humans before. However, serious adverse events in Phase 1 are still relatively rare — extensive preclinical testing (lab and animal studies) is required before human trials begin.
How long does each clinical trial phase take?
Phase 1: typically 6-12 months. Phase 2: 1-2 years. Phase 3: 2-4 years. Phase 4: ongoing (years). The entire drug development process from discovery to approval averages 10-15 years.
What percentage of drugs make it through all phases?
Approximately 10-15% of drugs that enter Phase 1 ultimately receive FDA approval. The biggest drop-off occurs between Phase 2 and Phase 3, where roughly 50-60% of drugs fail due to insufficient efficacy.
About This Data
Trial counts from ClinicalTrials.gov API v2. This is educational information — talk to your doctor about clinical trials. See our methodology.